Blog

Loncar Cancer Immunotherapy ETF (CNCR) Surpasses $50 Million in Assets Under Management – Business Wire (press release)

Loncar Cancer Immunotherapy ETF (CNCR) Surpasses $50 Million in Assets Under Management
Business Wire (press release)
Launched with a modest seed investment of $2.5 million on Oct. 13, 2015, the ETF has been offering exposure to public companies at the forefront of cancer immunotherapy research for more than two years. Cancer immunotherapy has become an important

and more »

2018-02-16 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.